Objective: A statistical clinical assessment of the effects of bilirubin and others hem catalyze biochemical parameters over the main signaling pathways involved in pancreatic head cancer to determine their carcinogenic impact using a molecular approach. Material and Methods: Patients’ data were collected at surgery department Sidi bel Abbes University Hospital (North Africa) patients were diagnosed with pancreatic cancer between 2013 and 2016. The data inclusion criteria were: Age, gender, medical history, surgical history, the year of diagnosis, as well as biological records such as: bilirubin, fibrinogen, creatinine and urea rates. Results: 44 patients with pancreatic cancer were included in our study (sex ratio=1.75). The mean age was 67.61 years. The most recorded medical history was diabetes with a rate of 43.2%, concerning surgical histories, 27.3% patients underwent a cholecystectomy. M1 was the most common diagnosis stage (27%). 81.81% of patients had hyperbilirubinemia, 6.81% had a normal bilirubinemia, 25% had high level of fibrinogen, 3.6% had a normal level. 77.3% had normal ureanemia, 18.2% had hyper-ureanemia and 15.9% had hypocreatininemia, 68.2% had normal level, 13.6% had hypercreatininemia. We matched patients’ groups with bilirubin level using Spearman’s correlation test and found a significant P value (P=0.015). We calculated the correlation between bilirubinemia and the stage of diagnosis, using the one-way ANOVA test and we found a significant P value (P=0.013). Conclusion: Our results represent an interesting shortcut to synthetize specific biochemical antibodies for bio-marking and diagnosis use, or even to lower serum level to reduce cancer aggressiveness.